{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:26Z","timestamp":1791924206541,"version":"4.3.4"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Mayo","award":["K2R"],"award-info":[{"award-number":["K2R"]}]},{"DOI":"10.13039\/100011542","name":"CCaTS","doi-asserted-by":"publisher","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}],"id":[{"id":"10.13039\/100011542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.1093\/ndt\/gfae257","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T02:43:28Z","timestamp":1731120208000},"page":"602-604","source":"Crossref","is-referenced-by-count":13,"title":["Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8146-0268","authenticated-orcid":false,"given":"Elena-Bianca","family":"Barbir","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjunmohan","family":"Mohan","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Koirala","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callen D","family":"Giesen","sequence":"additional","affiliation":[{"name":"Clinical Core Laboratory Services, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Lieske","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"2025030420322484300_bib1","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis\u2014treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025030420322484300_bib2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025030420322484300_bib3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025030420322484300_bib4","doi-asserted-by":"publisher","first-page":"e168950","DOI":"10.1172\/JCI168950","article-title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis","volume":"133","author":"Moledina","year":"2023","journal-title":"J Clin Invest"},{"key":"2025030420322484300_bib5","doi-asserted-by":"publisher","first-page":"e006222","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025030420322484300_bib6","doi-asserted-by":"publisher","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025030420322484300_bib7","doi-asserted-by":"publisher","first-page":"156006","DOI":"10.1016\/j.cyto.2022.156006","article-title":"Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: a systematic review and meta-analysis","volume":"158","author":"Gharamti","year":"2022","journal-title":"Cytokine"},{"key":"2025030420322484300_bib8","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025030420322484300_bib9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/B978-0-12-800094-6.00003-0","article-title":"Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule","volume":"63","author":"Norden","year":"2014","journal-title":"Adv Clin Chem"},{"key":"2025030420322484300_bib10","article-title":"Remicade (Infliximab) [package insert]. U.S. Food and Drug Administration website","author":"Janssen Biotech, Inc"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae257\/60548749\/gfae257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/3\/602\/60548749\/gfae257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/3\/602\/60548749\/gfae257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:37:10Z","timestamp":1741124230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/3\/602\/7887825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,11,8]]},"published-print":{"date-parts":[[2025,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae257","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,8]]}}}